secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001193125-22-279724
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics closes exclusive license agreement with GSK for tebipenem HBr
--------------------------------------------------------------------------------

- Received $66 million upfront payment from GSK under the exclusive license agreement.
- GSK affiliate purchased 7,450,000 shares of Spero common stock for approximately $9 million.
- Spero eligible for up to $525 million in development, sales, and commercial milestones plus tiered royalties.
- Spero will conduct a follow-up Phase 3 trial; GSK responsible for further development and commercialization outside Meiji Seika territories.
- GSK granted exclusive license to develop and commercialize tebipenem HBr in all territories except Japan and certain Asian countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522279724/0001193125-22-279724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522279724/d416179d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-279724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer